Article

Geminin, Ki67, and minichromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance.

Department of Microbiology and Pathology, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori, 683-8503, Japan.
Gastric Cancer (Impact Factor: 4.83). 08/2010; 13(3):177-85. DOI: 10.1007/s10120-010-0558-z
Source: PubMed

ABSTRACT Geminin negatively regulates Cdt1 and induces the formation of prereplicative complexes by loading mini-chromosome maintenance proteins (Mcm) onto chromatin and limiting DNA replication to once per cell cycle. Recent studies have suggested that geminin expression is a marker of the S/G2/M phase of the cell cycle and is associated with a poor prognosis in various human malignancies. This study aimed to clarify the pathobiological role of geminin in intestinal-type gastric carcinoma, and its relationships with minichromosome maintenance 2 (Mcm2) and Ki67 expression.
We performed western blot analysis of seven human gastric cancer cell lines, and immunohistochemical analysis of 72 gastric mucosal lesions and 128 surgically removed advanced intestinal-type gastric carcinomas. Double-labeling immuno-fluorescence was performed to identify the coexpression of geminin and Ki67.
Geminin was detected in all cell lines. Geminin labeling indices (LIs) in hyperplastic polyps, low-grade adenomas, high-grade adenomas, and intestinal-type adenocarcinomas were 3.9%, 10.5%, 18.6%, and 27.2%, respectively. The equivalent LIs for Ki67 and Mcm2 were 17.7%, 42.2%, 52.6%, and 59.7%; and 26.7%, 70.0%, 67.8%, and 77.8%, respectively. Double-labeling immunofluorescence revealed coexpression of geminin and Ki67 in both normal and tumor cells. The LI for geminin was significantly correlated with N stage, International Union Against Cancer (UICC) stage, Mcm2 LI, and Ki67 LI. Patients in stages I-IV and stage III with higher LIs for geminin (>25%) had significantly worse prognoses (P < 0.05 and P < 0.04, respectively). Univariate Cox regression analysis indicated that the overall survival of stage I-IV tumors was significantly correlated with high geminin LIs (relative risk [RR] = 1.94; P = 0.04).
Geminin expression might reflect the biological nature of gastric intramucosal neoplasms and could be a possible prognostic marker in advanced intestinal-type gastric carcinomas.

Download full-text

Full-text

Available from: Kanae Nosaka, May 26, 2014
0 Followers
 · 
112 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the role of Kit67, p53, topoisomerase II (TopoII) and glutathione S-transferase P1 (GSTP1) in predicting clinical outcome of advanced gastric cancer patients receiving capecitabine plus paclitaxel chemotherapy. The clinical data and tissue samples from 136 curatively resected advanced gastric cancer patients receiving capecitabine plus paclitaxel in the third affiliated hospital of Kunming medical university from January 2005 to December 2007 were retrospectively collected and analyzed for Kit67, p53, TopoIIa and GSTP1 expressions by immunohistochemistry. The relationships between expressions of the biomarkers and survival were analyzed. p53 expression were associated with the significantly shorter disease-free survival (DFS) (p<0.001) and overall survival (OS) (p=0.012) in the curatively resected advanced gastric cancer patients receiving capecitabine plus paclitaxel. Kit67, TopoIIa and GSTP1 expressions were not related to DFS and OS. p53 expression positive might predict prognosis in gastric cancer patients who underwent curative surgery followed by adjuvant capecitabine plus paclitaxel chemotherapy. A favorable effect of capecitabine plus paclitaxel might therefore be expected in patients that do not express p53.
    Hepato-gastroenterology 04/2012; 59(117):1327-32. DOI:10.5754/hge12204 · 0.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated geminin labeling index (LI) as a new prognostic indicator of pancreatic neuroendocrine tumor. Twenty-seven patients who underwent surgery were retrospectively referred. Labeling indices for geminin and Ki-67 were calculated and compared with clinicopathologic factors. Then, the concordance of positivity between 2 LIs was evaluated using the color difference quotation. The median (range) of LIs for geminin and Ki-67 was 1.0% (0.05%-14.9%) and 1.5% (0.02%-8.8%), respectively. When the high LI was defined as more than 2.0% according to the receiver operating characteristic curves determining the metastasis, both geminin LI (hazard ratio [HR], 31.382; 95% confidence interval [CI], 3.177-309.99; P = 0.003) and Ki-67 LI (HR, 6.182; 95% CI, 1.221-31.298; P = 0.028) were significant risk factors of recurrence in the univariate analysis. The Kaplan-Meier curves consistently exhibited the superiority of geminin LI (log rank, P < 0.001) to Ki-67 LI (log rank, P = 0.041) in predicting the disease-free survival. In the color difference quotation, the median ΔE of geminin stain (16.12; range, 5.8-41.9) was significantly larger than that of Ki-67 stain (13.17; range, 3.4-37.9). The geminin LI was suggested to be more closely correlated with outcome and had more consistent positivity than the Ki-67 LI.
    Pancreas 05/2012; 41(4):512-7. DOI:10.1097/MPA.0b013e31823ca3e0 · 3.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Triple-negative breast cancer, has a significant clinical relevance being associated with a shorter median time to relapse and death and does not respond to endocrine therapy or other available targeted agents. For this reason, identifying the molecular pathways associated with increased aggressiveness, for example the presence of stem cell populations within the tumor and alteration of genes associated with cell cycle regulation represents an important objective in the clinical research into this neoplasm. To investigate the role of cell cycle progression inhibitor Geminin in triple-negative breast cancers and its potential correlation with stem-like phenotype of this neoplasm, we used tissue microarray technology to build a specific triple-negative breast cancer tissue micro-array. Geminin and cancer stem cell marker CD133 expression was further investigated at the mRNA level for selected breast tumor samples through realtime polymerase chain reaction quantification. Our results showed that CD133 expression was significantly associated to high Geminin expression (p=0.017), a strong association between Ki-67 and tumor grade (p=0.020) and an inverse association between Geminin expression and lymphonode metastases (p=0.058), and a trend of statistically significance between Geminin marker expression and survival of triple-negative breast cancer patients (p=0.076). The strong association between the expression of CD133 and Geminin could be useful in molecular stratification of breast tumors and in particular of triple-negative breast cancers.
    06/2012; 15(2):162-71. DOI:10.4048/jbc.2012.15.2.162